Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
NF-κB: pivotal mediator or innocent bystander in atherogenesis?
Tucker Collins, Myron I. Cybulsky
Tucker Collins, Myron I. Cybulsky
Published February 1, 2001
Citation Information: J Clin Invest. 2001;107(3):255-264. https://doi.org/10.1172/JCI10373.
View: Text | PDF
Perspective

NF-κB: pivotal mediator or innocent bystander in atherogenesis?

  • Text
  • PDF
Abstract

Authors

Tucker Collins, Myron I. Cybulsky

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Schematic representation of NF-κB as an integrator in atherogenesis. Man...
Schematic representation of NF-κB as an integrator in atherogenesis. Many of the diverse agents associated with the onset of lesion formation interact with specific receptors. Angiotensin II (Ang II), cytokines, advanced glycosylation end products (AGEs), or oxidized lipids bind to the Ang II receptor (AT1), cytokine receptors, the receptor for AGEs (RAGE), or the scavenger receptor (SR), respectively. LPS interacts with a complex of LPS-binding protein (LBP), CD14 and a toll-like receptor (TLR). The mechanisms by which hemodynamic forces are perceived by vascular cells are only partially appreciated, but may involve specific receptors or links between the cytoskeleton, integrins, and ECM. Ligand binding by most of these receptors results in recruitment of adaptor proteins and activation of intermediate kinases (not shown). These events ultimately lead to the activation of an IKK complex. The best characterized kinase complex consists of IKK-α, IKK-β, and the structural component IKK-γ, although other similar complexes may exist. The activated IKK complex specifically phosphorylates the IκBs, which then undergo a rapid polyubiquitination process prior to degradation by the proteosome. Following release from the inhibitor, NF-κB dimers translocate from the cytoplasm to the nucleus, where they bind target genes and stimulate transcription of specific sets of genes relevant to the pathophysiology of the vessel wall.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts